Exenatide
approvedAlso known as: Byetta, Bydureon, Exendin-4
**Mechanism of Action** Exenatide is a synthetic version of exendin-4, a peptide originally isolated from the venom of the Gila monster (*Heloderma suspectum*). It acts as a potent and selective agonist of the glucagon-like peptide-1 (GLP-1) receptor, mimicking the actions of endogenous incretin hormones. By binding to GLP-1 receptors on pancreatic beta cells, exenatide enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety. Unlike native GLP-1, exenatide is resistant to degradation by dipeptidyl peptidase-4 (DPP-4), resulting in a prolonged half-life suitable for twice-daily (Byetta) or once-weekly (Bydureon) administration. **Key Research Findings** Clinical trials have demonstrated that exenatide significantly reduces fasting and postprandial glucose levels, lowers hemoglobin A1c (by ~0.8–1.5%), and promotes weight loss (average 2–5 kg) in patients with type 2 diabetes. Long-term studies (e.g., EXSCEL trial) showed cardiovascular safety, with a neutral effect on major adverse cardiac events. Preclinical and translational research has also explored exenatide’s neuroprotective effects in Parkinson’s disease and its potential to reduce hepatic steatosis in non-alcoholic fatty liver disease, though these remain investigational. **Clinical Relevance** Exenatide is FDA-approved as an adjunct to diet and exercise for glycemic control in type 2 diabetes, often used when metformin or sulfonylureas are insufficient. Its weight-loss benefit distinguishes it from older diabetes therapies. Common adverse effects include nausea, vomiting, and injection-site reactions; rare risks include pancreatitis and medullary thyroid carcinoma (based on rodent studies). Exenatide is contraindicated in patients with severe renal impairment or a personal/family history of medullary thyroid carcinoma. For research purposes only — not medical advice.
Key data
C184H282N50O60SResearch & studies
Semaglutide reduced HbA1c by 1.5% vs 0.9% with exenatide ER (ETD -0.62%, p<0.0001 for superiority).; Body weight decreased by 5.6 kg with semaglutide vs 1.9 kg with exenatide ER (ETD -3.78 kg, p<0.0001).; 67% of semaglutide-treated patients achieved HbA1c <7.0% vs 40% with exenatide ER.; Gastrointestinal adverse events were more common with semaglutide (41.8% vs 33.3%), while injection-site reactions were more frequent with exenatide ER (22.0% vs 1.2%).
Frequently asked questions
What is Exenatide?
**Mechanism of Action** Exenatide is a synthetic version of exendin-4, a peptide originally isolated from the venom of the Gila monster (*Heloderma suspectum*). It acts as a potent and selective agonist of the glucagon-like peptide-1 (GLP-1) receptor, mimicking the actions of endogenous incretin hormones. By binding to
How does Exenatide work?
Exendin-4-based GLP-1 receptor agonist from Gila monster venom; first-in-class incretin mimetic.
What is the research status of Exenatide?
Exenatide is currently classified as approved, with 2,783 research references on record. This is for research purposes only and is not medical advice.
What is the half-life of Exenatide?
The reported half-life of Exenatide is ~2.4 hours.
What is the molecular weight of Exenatide?
Exenatide has a molecular weight of approximately 4187 g/mol (formula C184H282N50O60S).
Related peptides
Once-daily acylated GLP-1 receptor agonist for type 2 diabetes and chronic weight management.
Long-acting GLP-1 receptor agonist that improves glycemic control, slows gastric emptying, and reduces appetite.
Dual GIP/GLP-1 receptor agonist delivering potent glucose lowering and weight reduction.
Once-weekly GLP-1 receptor agonist fused to an IgG4 Fc fragment for extended half-life.
Short-acting exendin-4-based GLP-1 receptor agonist with pronounced gastric-emptying delay.
Amylin analog adjunct to insulin that slows gastric emptying, suppresses glucagon, and increases satiety.
Build on Exenatide data programmatically
Structured peptide data, semantic search, and AI summaries via one API.
Get a free API key